Regulator warns of small risk of serious condition in people having RSV jab
It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over.
However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'.
In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.'
It warned staff to be alert to the signs and symptoms of the syndrome.
It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy.
The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill.
RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays.
The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women.
The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK.
Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints.
There may also be problems breathing and drooping face muscles or trouble swallowing or speaking.
Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo.
This is in the context of over 1.9 million doses of Abrysvo administered, it said.
Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date.
In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
a day ago
- Telegraph
Trump threatens NHS with higher drug prices
Donald Trump is pressuring the world's biggest drug makers to raise prices outside of the US in a threat to the NHS. The US president has written to pharmaceutical companies including Britain's GSK and AstraZeneca to demand they lower prices for Americans, suggesting they should pay for it by charging higher fees abroad. It raises the threat of higher costs for the NHS, which is one of the biggest buyers of pharmaceuticals in the world. In the letters sent to the bosses of 17 pharmaceutical companies, Mr Trump demanded that they 'negotiate harder with foreign freeloading nations' and said that 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He also demanded a 'binding commitment' to these goals and declared that 'other nations have been freeloading on US innovation for too long'. Mr Trump made clear that he would use tariffs to push through higher prices if countries resisted. The White House said the president was prepared to use 'trade policy to support manufacturers in raising prices internationally provided that increased revenues abroad are reinvested directly into lowering prices for American patients and taxpayers.' Drug companies have been set a 60-day deadline to 'step up' and meet the president's demands. He has also called for a commitment that companies 'will not offer other developed nations better prices for new drugs than prices offered in the United States.' Trung Huynh, the head of pharma analysis at UBS, said it was clear Mr Trump wanted companies to charge higher prices in the UK and Europe. Alex Schriver of US drug industry body PhRMA said: 'To reduce price differentials with other countries, policymakers should rein in health care middlemen driving up costs for Americans and get foreign countries to pay their fair share for innovative medicines.' Mr Trump has already targeted NHS drug prices as part of his tariff policy. Last month the Telegraph reported that the White House expected the NHS to pay higher prices for American drugs in an attempt to boost the interests of US corporates. Documents released after the US-UK trade agreement was signed earlier this year said the NHS would review drug pricing to take into account the 'concerns of the president'. Thursday's letter was sent to drug companies including Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer and Sanofi. Share prices slumped after Mr Trump published his letters on his Truth Social account. AstraZeneca and GSK both fell by more than 4pc, while Pfizer was down by more than 2pc. Mr Trump has long expressed rage about the fact that drug companies make between half and 70pc of their profits in the US despite the country accounting for only a fifth of global sales. Drug prices outside of the US can be as little as 30pc of what Americans pay. Profits from the US are used to fund drug research and development that the rest of the world benefits from. Mr Trump has claimed that US citizens effectively pay for foreign healthcare systems through higher drug prices. He said in 2020: 'In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidising socialism aboard [abroad] with skyrocketing prices at home. 'So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country.'
Daily Mail
2 days ago
- Daily Mail
GSK boss 'highly confident' sales will top £40bn by 2031 as firm cashes in on cancer and HIV drugs
GSK's boss said she was 'highly confident' sales will top £40billion by 2031 as the group cashes in on speciality medicines for cancer, HIV and other conditions. With the pharmaceuticals giant's HIV business as well as respiratory and oncology divisions recording double-digit revenue growth, Emma Walmsley said sales and profits are on course to be 'towards the top end' of expectations. Revenues rose 5 per cent to £15.5billion in the first half of the year and profits were up 41 per cent to £4.2billion. Shrugging off the impact of US tariffs, Walmsley added: 'With the breadth of our current business and the growth opportunities we have in our pipeline, we are highly confident in our outlook for sales of more than £40billion by 2031.' The updated guidance had taken into account the tariffs implemented and expected tariffs on European goods.
Times
2 days ago
- Times
GSK profits lifted by strong cancer drug sales
Strong sales of specialty medicines during the first half of the year has led GSK to expect group revenue and profit growth towards the top end of its forecast range. The FTSE 100 company posted total second quarter sales of almost £8 billion, up 6 per cent at constant currencies and ahead of City forecasts of £7.8 billion. Specialty medicines rose 15 per cent to £3.3 billion, including cancer treatments up 42 per cent and HIV drug sales 12 per cent. Core operating profit rose 12 per cent to £2.6 billion in the quarter. • Business live: FTSE 100 drops on poor corporate results The performance led GSK to forecast revenue growth this year towards the top end of its previously-guided range of between 3 and 5 per cent. Similarly it expects core operating profit growth to be towards the top of its 6 to 8 per cent range. GSK said that its guidance reflected tariffs already enacted and the US-EU trade deal struck this week, adding that it was 'positioned to respond to the potential financial impact of tariffs, with mitigation options identified. Given the uncertain external environment, we will continue to monitor developments'. On Monday, President Trump reiterated threats to introduce tariffs on pharmaceutical imports soon as he seeks to pressure multinationals to increase manufacturing in the United States. Dame Emma Walmsley, GSK's group chief executive, said that the 'strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business'. She added: 'We also continue to make very good progress in R&D, with three major FDA approvals achieved so far this year, 16 assets now in late-stage development, and four more promising medicines to treat cancer, liver disease and HIV expected to enter phase III and pivotal development by the end of the year.' A dividend of 16p per share was declared and GSK has spent £822 million on its £2 billion share buyback, which was announced at its full-year results earlier this year. Shares in GSK slid 8p, or 0.5 per cent, to £13.89 in early trading in London. Walmsley, 56, who has led GSK since 2017, said that the company remained confident in its its long-term outlook. GSK has set a target of generating group sales of more than £40 billion by 2031. However, there remains scepticism among some investors that it will hit that figure, with consensus forecasts instead of just £34 billion. It suffered a setback this month when the Food and Drug Administration, the regulator in America, the world's biggest drugs market, delayed a decision on approving Blenrep, a potential blockbuster blood cancer drug. The European Union, however, approved Blenrep for the treatment of adults with relapsed or refractory multiple myeloma. The UK has also given the green light. GSK, based in London's 'Knowledge Quarter', is one of Britain's two big pharma companies alongside AstraZeneca. It employs more than 65,000 people and operates in 75 markets. The group separated Haleon, its consumer healthcare business, as a standalone FTSE 100 company three years ago to focus on developing its core biopharma pipeline and to give it more firepower for bolt-on deals. On Monday it struck a $500 million deal with Hengrui Pharma, a Chinese pharmaceutical company, to develop up to a dozen new medicines as it deepens its partnerships in the country. GSK said on Wednesday that its agreement in May to pay up to $2 billion for a promising liver disease drug, the lead asset of Boston Pharmaceuticals, a US biopharma company, had been completed.
